Details of the Drug

General Information of Drug (ID: DMKD5ZO)

Drug Name
NN-8226
Synonyms
NNC-109-0012; IL-20 monoclonal antibody (inflammation), Novo Nordisk; Anti-IL20 (inflammation), ZymoGenetics/Novo Nordisk; Anti-IL20mAb (RA), ZymoGenetics/Novo Nordisk; Anti-interleukin-20 (rheumatoid arthritis), ZymoGenetics/Novo Nordisk
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D00LGA

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-20 (IL20) TTNZMY2 IL20_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Psoriasis vulgaris
ICD Disease Classification EA90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-20 (IL20) DTT IL20 1.82E-12 1.01 1.18
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02097264) A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. U.S. National Institutes of Health.
2 Handbook of Therapeutic Antibodies. 2014. 1. Page(995).